-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
We Think That There Are More Issues For Shandong Xinhua Pharmaceutical (HKG:719) Than Just Sluggish Earnings
We Think That There Are More Issues For Shandong Xinhua Pharmaceutical (HKG:719) Than Just Sluggish Earnings
A lackluster earnings announcement from Shandong Xinhua Pharmaceutical Company Limited (HKG:719) last week didn't sink the stock price. We think that investors are worried about some weaknesses underlying the earnings.
View our latest analysis for Shandong Xinhua Pharmaceutical
SEHK:719 Earnings and Revenue History September 6th 2022To understand the value of a company's earnings growth, it is imperative to consider any dilution of shareholders' interests. In fact, Shandong Xinhua Pharmaceutical increased the number of shares on issue by 6.7% over the last twelve months by issuing new shares. As a result, its net income is now split between a greater number of shares. To talk about net income, without noticing earnings per share, is to be distracted by the big numbers while ignoring the smaller numbers that talk to per share value. Check out Shandong Xinhua Pharmaceutical's historical EPS growth by clicking on this link.
How Is Dilution Impacting Shandong Xinhua Pharmaceutical's Earnings Per Share (EPS)?
Shandong Xinhua Pharmaceutical has improved its profit over the last three years, with an annualized gain of 22% in that time. Net income was down 2.8% over the last twelve months. But the EPS result was even worth, with the company recording a decline of 4.8%. Therefore, the dilution is having a noteworthy influence on shareholder returns.
If Shandong Xinhua Pharmaceutical's EPS can grow over time then that drastically improves the chances of the share price moving in the same direction. But on the other hand, we'd be far less excited to learn profit (but not EPS) was improving. For that reason, you could say that EPS is more important that net income in the long run, assuming the goal is to assess whether a company's share price might grow.
Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Shandong Xinhua Pharmaceutical.
Our Take On Shandong Xinhua Pharmaceutical's Profit Performance
Over the last year Shandong Xinhua Pharmaceutical issued new shares and so, there's a noteworthy divergence between EPS and net income growth. Because of this, we think that it may be that Shandong Xinhua Pharmaceutical's statutory profits are better than its underlying earnings power. Nonetheless, it's still worth noting that its earnings per share have grown at 19% over the last three years. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. So while earnings quality is important, it's equally important to consider the risks facing Shandong Xinhua Pharmaceutical at this point in time. In terms of investment risks, we've identified 2 warning signs with Shandong Xinhua Pharmaceutical, and understanding them should be part of your investment process.
This note has only looked at a single factor that sheds light on the nature of Shandong Xinhua Pharmaceutical's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying to be useful.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
一份平淡无奇的财报山东新华药业股份有限公司(HKG:719)上周股价没有下跌。我们认为,投资者担心的是盈利背后的一些弱点。
查看我们对山东新华药业的最新分析
联交所:719盈利及收入历史2022年9月6日要了解一家公司盈利增长的价值,必须考虑对股东利益的任何稀释。事实上,山东新华药业通过发行新股,在过去12个月中增加了6.7%的发行量。因此,它的净利润现在被更多的股票瓜分。谈论净利润,而不注意每股收益,就是被大数字分散注意力,而忽略了与之交谈的较小数字每股价值。点击此链接,查看山东新华医药历史上的每股收益增长情况。
稀释对山东新华药业每股收益(EPS)有何影响?
山东新华药业在过去三年里利润有所提高,同期年化收益为22%。净利润在过去12个月里下降了2.8%。但EPS的结果甚至是值得的,该公司录得4.8%的跌幅。因此,稀释对股东回报的影响是值得注意的。
如果山东新华药业的每股收益能够随着时间的推移而增长,那么这将极大地提高股价向同一方向变动的可能性。但另一方面,当我们得知利润(但不是每股收益)改善时,我们就不会那么兴奋了。出于这个原因,你可以说,从长远来看,每股收益比净利润更重要,假设目标是评估一家公司的股价是否可能增长。
注:我们总是建议投资者检查资产负债表的实力。点击此处进入我们对山东新华药业的资产负债表分析。
我们对山东新华药业盈利表现的看法
去年,山东新华药业发行了新股,因此,每股收益和净利润增长之间存在着值得注意的背离。正因为如此,我们认为可能是山东新华药业的法定利润好于其基础盈利能力。尽管如此,值得注意的是,它的每股收益在过去三年里以19%的速度增长。本文的目的是评估我们可以在多大程度上依赖法定收益来反映公司的潜力,但还有很多东西需要考虑。因此,尽管盈利质量很重要,但考虑山东新华药业目前面临的风险也同样重要。在投资风险方面,我们已经确定了两个警告信号与山东新华药业合作,了解他们应该是你投资过程的一部分。
这份报告只关注了一个因素,它揭示了山东新华药业的利润性质。但如果你有能力将注意力集中在细枝末节上,总会有更多的东西需要发现。一些人认为,高股本回报率是高质量企业的良好标志。虽然这可能需要为您做一些研究,但您可能会发现免费拥有高股本回报率的公司的集合,或者是内部人士购买的有用的股票清单。
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧